With rising popularity of rocuronium, this publication is a timely addition to debate regarding the ultimate paralytic in RSI. As we’ll see, the debate is definitely not settled. Rocuronium was demonstrated to be not non-inferior to succinylcholine. But we’ll see that extrapolating this study to general practice may be difficult. Depending on the camp you’re in, you may find succinylcholine gets one leg up on roc or you’ll identify one of many problems with this study that keeps rocuronium as your paralytic of choice.
Putting a fluid bolus during intubation into question, the Pragmatic Care Trials group and lead author Dave Janz re-examines yet another adage of “routine care.”
Jon Casey discusses the nuances of the PreVent trial and rebukes criticism.